Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 205,705,645 papers from all fields of science
Search
Sign In
Create Free Account
naftazone
Known as:
1,2-naphthoquinone-2-semicarbazone
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
6 relations
Narrower (4)
Etioven
Haemostop
Mediaven
Metorene
Broader (2)
Hemostatic Agents
Naphthoquinones
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Phlebotonics for venous insufficiency.
M. Martínez-Zapata
,
R. Vernooij
,
+5 authors
X. Bonfill Cosp
The Cochrane database of systematic reviews
2016
Corpus ID: 205168787
BACKGROUND Chronic venous insufficiency (CVI) is a common condition caused by valvular dysfunction with or without associated…
Expand
2012
2012
Synthesis, Characterization and Antiproliferative Activity of 1,2-Naphthoquinone and Its Derivatives
S. Shukla
,
R. Srivastava
,
S. Shrivastava
,
A. Sodhi
,
Pankaj Kumar
Applied Biochemistry and Biotechnology
2012
Corpus ID: 207354441
In the present study substituted 1,2-naphthoquinones were synthesized, purified and characterized by spectroscopic studies (UV…
Expand
2012
2012
A proof‐of‐concept, randomized, placebo‐controlled, multiple cross‐overs (n‐of‐1) study of naftazone in Parkinson’s disease
O. Rascol
,
J. Ferreira
,
+7 authors
L. Bossi
Fundamental & clinical pharmacology
2012
Corpus ID: 26243905
To explore for the first time the tolerability and efficacy of naftazone in patients with Parkinson’s disease (PD). Proof‐of…
Expand
Review
2005
Review
2005
Phlebotonics for venous insufficiency.
M. J. Martínez
,
X. Bonfill
,
R. M. Moreno
,
E. Vargas
,
D. Capellà
The Cochrane database of systematic reviews
2005
Corpus ID: 37460543
BACKGROUND Chronic venous insufficiency (CVI) is a common condition caused by inadequate blood flow through the veins, usually in…
Expand
1997
1997
Placebo-Controlled Trial of Naftazone in Women with Primary Uncomplicated Symptomatic Varicose Veins
M. Vayssairat
1997
Corpus ID: 78488214
Objective: To evaluate the effectiveness and best time course of prescription of 30 mg/day oral naftazone (N) in women with…
Expand
1996
1996
In‐vitro and Ex‐vivo Inhibition of Blood Platelet Aggregation by Naftazone
P. Durand
,
C. Bloy
,
F. Peltier-Pujol
,
D. Blache
The Journal of pharmacy and pharmacology
1996
Corpus ID: 34569293
Because of the considerable interest in the role of platelets and antiplatelet therapy in cardiovascular disease, including the…
Expand
1995
1995
Reduction and glucuronidation of naftazone by human and rat liver microsomes.
R. Herber
,
B. Hercelin
,
+4 authors
J. Magdalou
Drug metabolism and disposition: the biological…
1995
Corpus ID: 26475148
Reduction and glucuronidation of the vasoprotectant drug, naftazone, by human and rat liver microsomes and by recombinant UDP…
Expand
1994
1994
Modification of the Dissolution Behaviour of a Water‐insoluble Drug, Naftazone, for Zero‐order Release Matrix Preparation *
P. Giunchedi
,
L. Maggi
,
A. Manna
,
U. Conte
The Journal of pharmacy and pharmacology
1994
Corpus ID: 20189133
Abstract— The preparation of hydrophilic matrix tablets able to release naftazone, a water‐insoluble drug, into an aqueous medium…
Expand
1982
1982
Study of semicarbazones and thiosemicarbazones derived from 1,2-naphthoquinone, as acid-base indicators: Evaluation of their transition limits through the chromaticity co-ordinates.
A. Izquierdo
,
E. Bosch
,
V. Rodrigo
Talanta
1982
Corpus ID: 37102962
1971
1971
[Syntheses of 1,2-naphthoquinone-2-semicarbazone and its related compounds, and their reaction with metals].
T. Ueda
,
A. Takada
,
K. Kosugi
Yakugaku zasshi : Journal of the Pharmaceutical…
1971
Corpus ID: 33471852
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE